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Lung cancer is the common fatal illness with the highest incidence and mortality 
globally. Epidermal growth factor receptor overexpression by tumor cells is associated 
with uncontrolled proliferation, angiogenesis, anti-apoptotic signals, metastization, 
and invasiveness. CIMAvax-EGF vaccine consists of a chemical conjugate of the EGF 
with the P64 protein derived from the Meningitis B bacteria and Montanide ISA 51, 
as adjuvant. The vaccine is projected to induce antibodies against EGF that results in 
EGF withdrawal. CIMAvax-EGF demonstrated to be safe and immunogenic in advanced 
non-small cell lung cancer (NSCLC) patients. The efficacy study was an open-label, mul-
ticentric Phase III clinical trial, which enrolled 405 advanced NSCLC patients. Patients 
with proven stage IIIB/IV NSCLC, who had completed four to six cycles of chemotherapy 
(CTP) were randomized to receive CIMAvax-EGF or best supportive care. CIMAvax-EGF 
resulted in a significantly larger overall survival in patients receiving at least four doses. 
High EGF concentration at baseline was a good predictive biomarker of the vaccine 
activity and a poor prognostic biomarker for the non-treated population. The proportion 
of CD8+CD28− cells, CD4 cells, and the CD4/CD8 ratio after first-line CTP was also 
associated with CIMAvax-EGF clinical benefit. After completing the Phase III, a Phase IV 
trial was done where the vaccine was administered in primary care units. Administering 
the vaccine at primary care institutions granted better access and treatment compliance. 
Safety was confirmed. Several clinical trials are currently ongoing to validate EGF as a 
predictive biomarker of CIMAvax-EGF efficacy.
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THe ROLe OF CHeCKPOiNT iNHiBiTORS (CPis) iN THe 
CONTROL OF NON-SMALL CeLL LUNG CANCeR (NSCLC)
The strategy of triggering the immune system to control tumor progression is not new in cancer 
research but has been characterized by alternating trends of excitement or frustration. BCG, 
interferon, and interleukin-2 provided clinical evidences of antitumor activity, but their role in the 
oncology practice remained limited to few tumor localizations (1, 2). With the advent of immune 
“check-points” inhibitors, cancer immunotherapy has proven to radically increase the survival of 
patients bearing advanced melanoma, lymphoma, renal, lung, urothelial, and head and neck tumors 
(3, 4). Immunotherapy represents an “unconventional” way of treating cancer by targeting the 
immune system, not the tumor itself (5). The hypothesis is that hindering the “switch-off ” receptors 
like CTLA-4 and PD1 in the lymphocytes, would set the immune system free to destroy cancer. 
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Antibodies against CTLA-4, progressive disease (PD)-1 (pro-
grammed death), and PD-1 ligands (PD1-L) represent a major 
step forward and are the first examples of broadly effective and 
durable cancer immunotherapies (5, 6).
Lung cancer is the common fatal illness with the highest 
incidence and mortality globally. NSCLC is the most common 
histological type of lung cancer (7). Albeit NSCLC is not a clas-
sical “immune-sensitive” cancer like melanoma or renal cell 
carcinoma, two anti-PD1 antibodies and one anti-PD1L antibody 
have been approved for the treatment for patients with advanced 
disease.
Nivolumab, a PD-1 CPI, was evaluated in a Phase III study 
in patients with non-squamous NSCLC that progressed during 
or after platinum-based doublet chemotherapy (CTP). Overall 
survival was longer with nivolumab than with docetaxel, a taxane 
derivative that inhibits the polymerization of microtubules. The 
median overall survival was 12.2 months in the nivolumab group 
and 9.4 months in the docetaxel group (8). As well, patients with 
advanced squamous cell NSCLC who have PD after first-line CTP 
were randomized to receive nivolumab or docetaxel. The median 
overall survival was 9.2 months with nivolumab vs. 6.0 months 
with docetaxel (9).
On the other hand, patients with previously treated NSCLC 
and PD-L1 expression on at least 1% of tumor cells were 
randomized to receive pembrolizumab (a different anti-PD1 
antibody) at two-dose levels. Overall survival was significantly 
larger for pembrolizumab, at the two evaluated doses. Median 
overall survival was 10.4 months with pembrolizumab at 2 mg/kg, 
12.7 months after pembrolizumab at 10 mg/kg and 8.5 months 
after receiving docetaxel. In patients with at least 50% of cells 
expressing PD-L1, median survival time (MST) was better with 
pembrolizumab (10).
Moreover, in patients with newly diagnosed stage IIIB/IV 
NSCLC and PD-L1 expression on 50% of cancer cells, pembroli-
zumab was associated with significantly longer progression-free 
and overall survival as compared to platinum-based CTP. A total 
of 305 patients were randomly allocated to platinum CTP or pem-
brolizumab. Patients in the pembrolizumab group had a median 
PFS of 10.3 months, compared to 6.0 months for the CTP group. 
The 6 months overall survival was 80.2% in the pembrolizumab 
arm vs. 72.4% in the CTP arm (11).
Finally, FDA has lately accepted atezolizumab (an anti-PD1L 
antibody) for treating CTP-refractory, metastatic NSCLC 
patients. The approval followed the findings from the randomized 
Phase III OAK and Phase II POPLAR clinical trials, indicating 
a median 4.2  months survival advantage over docetaxel CTP 
(MST in OAK trial: 13.8 vs. 9.6 months). OAK study participants 
included patients with varying PD-L1 status and both squamous 
and non-squamous tumors (12, 13).
In summary, three immunomodulatory drugs, two anti-PD1 
antibodies (nivolumab and pembrolizumab), and one anti-PD1 
ligand antibody (atezolizumab), have shown to improve the 
survival of advanced NSCLC, still considered an unmet medical 
need. Table 1 summarizes the most important results of the three 
CPIs approved so far for second- or first-line therapy of advanced 
NSCLC patients.
eGF/ePiDeRMAL GROwTH FACTOR 
ReCePTOR (eGFR) SYSTeM AND 
CiMAvax-eGF MeCHANiSM OF ACTiON
Oncogenic mutations have arisen as key therapeutic targets for 
molecular treatments in several cancers (14). EGFR, a well-
validated oncogene, is a 170-kDa membrane glycoprotein. The 
intracellular domain is associated with protein tyrosine kinase 
activity, and its overexpression by tumor cells alters the regulation 
of the cell cycle, blocks apoptosis, promotes angiogenesis, and 
increases the motility and invasiveness of the tumor cells (15).
Therefore, EGFR as well as its downstream mediators have been 
identified as important therapeutic targets. The approved small-
tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib (Iressa™), 
erlotinib (Tarceva™), and afatinib (tykerb™), are effective in a 
group of NSCLC patients whose tumors carry stimulating muta-
tions within the kinase domain of EGFR (16–19). EGFR–TKIs 
are the best option as front-line therapy in EGFR mutant NSCLC 
patients. In pretreated NSCLC, EGFR–TKIs are more effective 
than conventional cytotoxic therapy, in existence of EGFR muta-
tions (16–19). EGFR has seven known ligands, among which, 
EGF is one of the most critical (20, 21).
The strategy of “sequestering” EGF reproduces the “hormonal 
castration” therapy, known to be effective in hormone-dependent 
tumors such as breast and prostate, thus extending this concept to 
other types of malignant tumors.
The mechanism of action of CIMAvax-EGF consists on the 
formation of antibodies against EGF, breaking the tolerance to 
a self-protein. This is possible because the vaccine consists on a 
chemical conjugate of the recombinant EGF with the P64k protein 
derived from the Neisseria meningitidis (conjugate EGF-P64K) 
(Figure 1) and the adjuvant Montanide ISA 51 (22). CIMAvax-
EGF is administered by the intramuscular route, at four injection 
sites (22, 23).
CIMAvax-EGF vaccine exerts its anti-cancer activity by 
targeting the immune system, inducing anti-EGF antibodies that 
result in the decline of the circulating EGF in sera (23, 24). This, 
in turn, significantly decreases the probability that the remaining 
EGF binds to its receptor (EGFR) on the surface of cancer cells. 
EGF withdrawal results in the loss of a key pro-proliferation and 
pro-survival signal for the neoplastic cells (23, 24). The vaccine 
has demonstrated to be safe and immunogenic in more than 
5,000 advanced NSCLC patients (23, 24).
CIMAvax-EGF was approved as a maintenance treatment for 
patients with stage IIIB/IV NSCLC, after front-line CTP.
Two randomized studies have been completed so far. The Phase 
II clinical trial included 80 advanced NSCLC patients: 40 vacci-
nated and 40 treated with supportive care. Patients joined the trial 
after finalizing first-line CTP, regardless their objective response. 
CIMAvax-EGF was non-toxic and induced anti-EGF antibodies. 
Vaccinated subjects showed a trend toward better survival, which 
was not statistically significant at this sample size (25).
The efficacy study consisted in an open-label, multicentric 
Phase III clinical trial, which enrolled 405 advanced NSCLC 
patients, at 21 research sites. Patients with proven stage IIIB/
IV NSCLC, who received four to six cycles of platinum-based 
FiGURe 1 | CiMAvax-eGF composition. CIMAvax-EGF therapeutic vaccine consist on a chemical conjugate of the EGF with the P64K protein derived from 
Neisseria meningitidis.
TABLe 1 | CPis in the treatment of patients with advanced NSCLC.





Non-squamous NSCLC patients that progressed during or after platinum-
based doublet chemotherapy (CTP)
Nivolumab Docetaxel 12.2 9.4
Squamous NSCLC patients that progressed during or after platinum-based 
doublet CTP
Nivolumab Docetaxel 9.2 6
Previously treated NSCLC with progressive disease (PD)-L1 expression on at 









CTP-refractory, metastatic NSCLC Atezolizumab Docetaxel 13.8 9.6
Previously untreated advanced NSCLC with PD-L1 expression on at least 
50% of tumor cells
Pembrolizumab 
(200 mg)
Carboplatin plus pemetrexed, 
cisplatin plus pemetrexed, 
carboplatin plus gemcitabine, 
cisplatin plus gemcitabine, 
carboplatin plus paclitaxel
6 months 6 months
SV rate: 80.2% SV rate: 
72.4%
NSCLC, non-small cell lung cancer; CPI, checkpoint inhibitor; MST, median survival time.
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CTP were randomized to vaccine arm [CIMAvax-EGF plus best 
supportive care (BSC)] or to control arm (BSC alone). Primary 
endpoint was overall survival while secondary endpoints were the 
assessment of serum EGF concentration, immunogenicity, and 
safety. All lung cancer patients completed front-line CTP achiev-
ing stable disease, partial, or complete response of the target 
lesions. Most subjects had cisplatin/carboplatin in combination 
with vinblastine, etoposide, or paclitaxel. Randomization (EGF 
cancer vaccine vs. BSC) was unbalanced (2:1), given the prelimi-
nary evidence of survival advantage shown in the Phase II study. 
Vaccine schedule consisted in four biweekly doses (induction 
phase) followed by monthly reimmunizations (maintenance). 
Cyclophosphamide was administered before vaccination at a 
low, immunomodulatory dose (200  mg/m2). Vaccination was 
maintained until severe patient condition worsening (PS = 3) or 
unmanageable toxicity (26).
This study was registered in the National Public Registry of 
Clinical Trials; a WHO-validated public registry (http://www.
who.int/ictrp/network/rpcec/en, RPCEC00000161). In total, 
270 vaccinated and 135 controls were enrolled in the Phase III 
study. Both groups were well balanced according to the most 
important prognostic variables. The majority of the patients 
were men, current, or past smokers, with an ECOG performance 
status of 1. The most prevalent histology was squamous cell 
carcinoma, and they had stable disease or partial response after 
first-line platinum doublet. Vaccination was safe, and the most 
common adverse reactions were mild or moderate injection site 
events, fever, headache, chills, vomiting, and general malaise. 
CIMAvax-EGF significantly augmented overall survival when 
the Harrington–Fleming test was applied (26). The Harrington–
Fleming is a weighted log-rank test that can be used once the 
non-proportionality of the hazard ratio is confirmed (27, 28). 
This waited log-rank is the ideal test when there is a deferred split 
of the time to event curve (27, 28). This is the case of therapeutic 
cancer vaccines or immune-modulatory drugs, which effect may 
manifest several months after the intervention. In this scenario, 
the projected hazard ratio does not apply from the beginning 
but at the separation of both curves. MST was 10.83 months for 
vaccinated vs. 8.86 months for non-vaccinated. In the Phase III 
trial, the 5-year survival rate was 14.4% for vaccinated subjects 
TABLe 2 | CiMAvax-eGF in the treatment of patients with advanced NSCLC (Phase iii clinical trial).





Stage IIIB/IV NSCLC patients, with at least stable disease after CTP (ITT) CIMAvax-EGF BSC 10.83 8.86
Stage IIIB/IV NSCLC patients, with at least stable disease after CTP (PP) CIMAvax-EGF BSC 12.43 9.43
Stage IIIB/IV NSCLC patients, with at least stable disease after CTP. Patients 
with (EGF) > 870 pg/ml
CIMAvax-EGF BSC 14.66 8.63
NSCLC, non-small cell lung cancer; MST, median survival time; PD, progressive disease; CTP, chemotherapy; BSC, best supportive care.
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vs. 7.9% for controls. The advantage was larger in those patients 
that completed vaccination induction consisting in four doses 
(“per protocol” scenario). The “per protocol” scenario is very 
relevant for CIMAvax-EGF given that several doses are required 
to break the tolerance and induce a protective response. MST was 
12.43  months for vaccinated subjects completing induction vs. 
9.43 months, for control patients (Table 2). Those controls that 
did not survived for at least 42 days (vaccine induction time) were 
excluded from the analysis. The 5-year survival rate was 16.62% 
for vaccinated patients vs. 6.2% for controls. A subgroup analysis 
considering demographic or tumor variables was done, and the 
larger gain was seen in smoker patients bearing squamous cell 
carcinomas with an ECOG 1 (26).
CiMAvax-eGF iMMUNOGeNiTY AND 
PReDiCTive BiOMARKeRS OF eFFiCACY
Immune response was characterized in patients treated with 
CIMAvax-EGF (24). Anti-EGF antibodies induced by CIMAvax-
EGF inhibited EGF–EGFR binding and abrogated EGFR activa-
tion (Figure 2). After immunization, there was a decrease in the 
circulating EGF which was inversely correlated with the antibody 
response. Antibody response also correlated with survival benefit 
since those patients displaying higher antibody titers exhibited 
better survival (24).
In the Phase III trial, a large proportion of patients (78.8%) 
met the good antibody response (GAR) condition (anti-EGF 
antibody titers  ≥  1:4,000 sera dilution). GAR condition was 
associated with longer survival in the preceding exploratory and 
Phase II trials. The geometric mean of the maximum antibody 
titers was 1:12,646 sera dilution, while the maximum anti-EGF 
titer was 1:1,024,000. Patients developing a GAR as soon as day 
32 had a significant survival benefit (MST =  27.28 months) as 
compared to controls (26).
The functionality of anti-EGF antibodies was also evaluated. 
Sera from vaccinated patients inhibited the binding between EGF 
and its receptor. Median binding inhibition capacity was 20 and 
40% after 5 and 12 months from vaccination, respectively (24). 
Furthermore, post-immune sera abrogated EGFR phosphoryla-
tion. Median phosphorylation inhibition was 65 and 85% after 5 
and 12 months, respectively (24).
To discern the immune dominance of the antibody response 
induced by vaccination, several peptides mimicking the main 
EGF epitopes were synthesized. Sera from vaccinated patients 
were then tested for binding to the peptides in an enzyme-linked 
immunosorbed assay. In the Phase III study, 46% of the patients 
showed an immune-dominant response against the loop B of the 
EGF molecule (26).
The immune response of 19 long-term (more than 2  years) 
NSCLC survivors, regularly treated with CIMAvax-EG, was 
assessed (29). Previous studies showed that the anti-EGF 
antibody titers increased in vaccinated patients after repeated 
immunizations, until a plateau is reached (24–26). In long-term 
vaccinated patients, the anti-EGF antibody response remained 
high, reaching a plateau at 1:10,000 sera dilution. Although a 
deferred decrease in antibody titers was found in one third of 
the uninterrupted vaccinated patients, for the majority (two-
thirds), there was no evidence of clonal exhaustion after 2 years 
of monthly vaccination. The immunodominance of the antibody 
response induced by CIMAvax-EGF was tested in long-term vac-
cinated subjects. The predominant response was against the loop 
B, which is the main binding site of EGF to EGFR. Long-lasting 
vaccination resulted in a reduction of serum EGF level. EGF 
concentration decreased to undetectable values in all continued 
vaccinated patients (29).
In summary, prolonged vaccination with CIMAvax-EGF 
induced high anti-EGF antibodies, capable to maintain 
serum EGF in undetectable levels. Toxicity was not exacer-
bated with lengthy vaccination. Long-term “EGF deficiency” 
did not result in deleterious effect for normal tissues. 
Previously, it was published that the lack of EGF produces 
delayed development of fetal tissue but no injury on healthy 
adult tissues (30).
During the last decade, the scientific community has been 
working hard on the development and evaluation of biomarkers 
for cancer drug development (31).
Several attempts have been done to find predictive biomark-
ers of clinical benefit of CIMAvax-EGF. Vaccinated patients with 
serum EGF concentration >870 pg/ml showed larger survival as 
compared with controls with the same EGF serum level. MST in 
this patient population was 14.66 months, as large as the survival 
of patients receiving other drugs as continuation or switch main-
tenance (26). MST was 8.63  months for those control patients 
with EGF concentration greater than 870  pg/ml (Table  2). 
Five-year survival rate for patients with high (EGF) was 23% for 
vaccinated patients, while no controls were alive at the referred 
time interval. The association between EGF levels and prognosis 
remained significant when the prognostic variables (gender, 
smoking history, performance status, and staging) were included 
in the multivariate analysis (26).
FiGURe 2 | CiMAvax-eGF mechanism of action. Anti-EGF antibodies induced by CIMAvax-EGF inhibit EGF–epidermal growth factor receptor (EGFR) binding 
and abrogate EGFR activation.
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On the other hand, control patients with a high (EGF) had 
a significantly shorter survival (8.63 months) as compared with 
non-treated subjects with low (EGF) at baseline (15.06 months). 
In summary, the Phase III trial demonstrated that the EGF level 
in patients’ sera could be simultaneously a biomarker of poor 
prognosis and a predictive factor of CIMAvax-EGF benefit. This 
result confirms the role of the EGF in the biology of the tumor 
but also provides a biomarker for selecting patients who benefit 
largely from vaccination with CIMAvax-EGF (26).
The impairment of immune system of cancer patients induced 
by the tumor together with the previous oncological therapies 
is largely proven. The evaluation of immunocompetence would 
provide evidences of which patients are going to benefit from 
immunotherapy (32). A deficit in the number of B cells, a reduced 
CD4/CD8 ratio and an increase in late-stage differentiated cells 
such as CD8+CD28− T cells distinguish the “immune-compro-
mised” profile (33). In that logic, besides EGF concentration, the 
proportion of CD8+CD28− T cells, CD4 T cells, and the CD4/
CD8 ratio after CTP was correlated with the clinical benefit of 
CIMAvax-EGF (33).
Vaccinated patients with CD4+ T  cells counts greater than 
40%, CD8+CD28− T cells counts lower than 24% and a CD4/
CD8 ratio >2 after first-line platinum-based CTP, achieved a 
significantly large median survival, as compared to controls 
with the same phenotype. MST was 46.4 months for vaccinated 
patients with CD4+ counts >40% vs. 12.3 months for the matched 
controls, 37.2 vs. 14.3 months for vaccinated and controls with 
CD8+CD28− T cells counts <24% and 50.4 vs. 14.3 months for 
treated vs. non-treated patients with CD4/CD8 ratio >2 (33).
These findings highlight the potential value of T cell subpopu-
lations and EGF serum levels, measured after front-line CTP, as 
predictive biomarkers of CIMAvax-EGF efficacy.
COMBiNiNG CTP AND CiMAvax-eGF
CIMAvax-EGF is commonly administered after patients have 
finished first-line CTP. However, it would be important to start 
vaccination earlier in the course of the disease, given that the vac-
cine requires time to elicit a neutralizing response. In that sense, 
CIMAvax-EGF was administered concurrently with platinum 
doublets or even, before CTP (34). In addition, CTP and cancer 
vaccines could be additive through different mechanisms: by 
decreasing immunosuppressive cells such as T-regulatory and 
myeloid-derived suppressor cells, by stimulating massive antigen 
release leading to effective cross-priming, by modifying the 
tumor microenvironment and by augmenting the T-cells traffic 
of into the tumors (35). Oxaliplatin and cisplatin can stimulate 
antitumor responses, through the induction of immunogenic 
cell death (35). The release of new antigens can activate dendritic 
cells, which in turn, that activate cytotoxic lymphocytes (35, 36).
Dose-dense platinum CTP did not affect CIMAvax-EGF 
capacity to induce a potent antibody response. Immunogenicity 
in terms of percentage of good responders or immunodominance 
against loop B was better after vaccinating concurrently or before 
CTP, as compared to the standard sequential platinum doublets 
and vaccination (34). Increased immunogenicity could be 
explained by the earlier unset of vaccination or by the potentiat-
ing effect of the cytotoxic drugs.
CiMAvax-eGF iN PRiMARY CARe UNiTS 
AND FUTURe PeRSPeCTiveS
After completing the Phase III, a Phase IV trial was launched 
where the family medicine physicians administered CIMAvax-
EGF in primary health care units (policlinics). In total, 45 primary 
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level units together with 24 secondary level units (hospitals) 
participated in the study that enrolled more than 1,000 patients in 
3 years. This study was registered in the National Public Registry 
of Clinical Trials (http://www.who.int/ictrp/network/rpcec/en, 
trial number RPCEC00000181). Administering the vaccine at 
primary care institutions granted better access and treatment 
compliance. Safety was confirmed; the most frequently reported 
adverse events were pain at the site of injection followed by fever, 
headache, chills, nausea, and dyspnea (22).
Overall survival of those patients that received at least one 
vaccine dose was 13.9 months (mean) and 7.0 months (median). 
Survival rate at 12 and 24 months was 34.8 of 18.1%, respectively. 
On the other hand, the overall survival of patients receiving at least 
the induction doses was 16.93 months (mean) and 9.9 months 
(median). The 12 and 24 months survival rate was of 44.1 and 
23.3%, respectively.
In summary, CIMAvax-EGF was safe in patients with NSCLC 
at advanced stages treated in primary care facilities. The safety 
profile coincided with the previously described in controlled 
studies. CIMAvax-EGF also showed benefit in terms of survival, 
mainly in those subjects that completed four vaccine doses. 
Treatment with CIMAvax-EGF resulted in preliminary evidences 
of improvement in the quality of life, which was significant for 
the emotional functioning and the fatigue symptom. The use of 
medications to control pain was stable during vaccination (22).
Several clinical trials are currently ongoing. A new Phase III 
trial (WHO-validated public registry; http://www.who.int/ictrp/
network/rpcec/en, trial number RPCEC00000208) is open for 
enrollment, where CIMAvax-EGF is used as switch maintenance 
in patients completing front-line CTP that has EGF concentration 
higher than 870 pg/ml (enrichment design). The main goal of the 
trial is to prospectively validate EGF as a predictive biomarker. 
In this scenario, the randomization is unbalanced (3:1) given the 
previous evidences of the clinical benefit of the vaccine. In addi-
tion, a new Phase IV (WHO-validated public registry; http://www.
who.int/ictrp/network/rpcec/en, trial number PCEC00000205) 
was launched in 178 policlinics (at least one investigation site per 
state municipality) and 25 hospitals. Patients will be recruited by 
the oncologists in the specialized oncology services, but will be 
treated in their neighborhood, at the primary health care facili-
ties. The aim is to grant vaccine access and to improve treatment 
compliance. In this trial, EGF concentration will be measured 
but not as an inclusion criterion. Instead, EGF at baseline will be 
retrospectively correlated with the clinical efficacy. An EGF quan-
tification system was developed in the country by the National 
Center for Immunoassay, to accompany the vaccine prescription 
(37). Both studies will permit the consolidation of the scientific 
evidence of the EGF as a biomarker. Other translational studies 
are planned to gather more information on the relevance of the 
lymphocyte subpopulation as well as the individual tumor biology 
(mainly associated with EGFR mutations) for the CIMAvax-EGF 
efficacy.
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